We identified four indications for 68Ga-DOTA: (1) Post-operative assessment: defined as any scan performed within 12 months of surgery (n = 13); (2) Routine surveillance: defined as surveillance imaging performed >12 months post-operatively without a specific indication (n = 17); (3) Recurrence suspected based on cross-sectional imaging findings suspicious for recurrent or metastatic disease (n = 10); (4) Recurrence suspected based on biochemical monitoring with serum chromogranin A and/or 24 h urine 5HIAA (n = 6). The gene discussed is CHGA; the disease is metastatic neoplasm.